DCTH
DELCATH SYSTEMS, INC.
NASDAQ · Healthcare · Medical - Devices · US
$14.37
+2.06%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$14.16
From 52W high−17.22%
Volume300137.00
Market cap$498.62M
P/E (TTM)1306.4x
P/S (TTM)5.2x
Div yield—
Key dataOct 19, 2026
Open
$14.16
From 52W high
−17.22%
Volume
300137.00
Market cap
$498.62M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
225.9x
P/E (TTM)
1306.4x
RSI (14)
38.0
MomentumView details →
1D Return
+2.06%
YTD Return
+42.18%
SummaryUpdated Jun 1, 2026
Delcath Systems, Inc. (NASDAQ:DCTH) is a specialized interventional oncology company founded in 1988 and headquartered in New York, New York. The company focuses on developing and commercializing innovative treatments for primary and metastatic liver cancers. After decades of development, Delcath achieved a major milestone in 2024 with the U.S. commercial launch of its flagship product HEPZATO KIT, following FDA approval for treating metastatic uveal melanoma. The company also markets its technology in Europe under the CHEMOSAT brand name and is actively expanding its clinical programs to address additional cancer indications.
Similar companies
Latest newsMore news →
Delcath Systems announced that presentations on its clinical development programs will take place at the ESMO Congress 2026, scheduled for October 23–27 in Madrid.3h agoDelcath Systems, Inc. reported Q2 2026 earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share.74d ago